Vaccinex's average Accounts Receivable for the
three
months ended in Dec. 2024 was $0.91 Mil. Vaccinex's Revenue for the
three
months ended in Dec. 2024 was $0.21 Mil.
Hence, Vaccinex's Days Sales Outstanding for the
three
months ended in Dec. 2024 was 390.49.
The historical rank and industry rank for Vaccinex's Days Sales Outstanding or its related term are showing as below:
VCNX'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 63.67 Med: 363.72 Max: 3850.75
Current: 802.15
During the past 9 years, Vaccinex's highest Days Sales Outstanding was 3850.75. The lowest was 63.67. And the median was 363.72.
VCNX's Days Sales Outstanding is ranked worse than 96.34% of 847
companies
in the Biotechnology industry
Industry Median: 72.78
vs VCNX: 802.15
Vaccinex's Days Sales Outstanding
increased
from Dec. 2023 (0.00) to Dec. 2024 (390.49).
Warning Sign:
If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.
Vaccinex Days Sales Outstanding Historical Data
The historical data trend for Vaccinex's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Vaccinex's Days Sales Outstanding
For the Biotechnology subindustry, Vaccinex's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vaccinex's Days Sales Outstanding Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vaccinex's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Vaccinex's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vaccinex (OTCPK:VCNX) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Vaccinex Days Sales Outstanding Related Terms
Thank you for viewing the detailed overview of Vaccinex's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VCNX has been successfully added to your 